Back to today’s briefing

Story perspectives

Retro Biosciences Secures $1 Billion for Alzheimer's Breakthrough

1/26/2025

49 7

Summary

Story summary

Retro Biosciences has made waves by securing a staggering $1 billion in funding to tackle age-related diseases, with an exciting Alzheimer's treatment set to enter trials in Australia. Supported by notable investors like OpenAI's Sam Altman, the San Francisco company harnesses AI to craft proteins that could rejuvenate cells. CEO Joe Betts-LaCroix is determined to launch the first drug by the 2020s, igniting hope for a healthier future.

1 of 1

Story summary

Retro Biosciences has made waves by securing a staggering $1 billion in funding to tackle age-related diseases, with an exciting Alzheimer's treatment set to enter trials in Australia. Supported by notable investors like OpenAI's Sam Altman, the San Francisco company harnesses AI to craft proteins that could rejuvenate cells. CEO Joe Betts-LaCroix is determined to launch the first drug by the 2020s, igniting hope for a healthier future.